Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
News|Articles|December 9, 2025
AI in Dermatology: Discussing Downsides to the Adoption of Artificial Intelligence
Author(s)Tim Smith
Fact checked by: Patrick Campbell
Explore the evolving role of AI in dermatology, balancing its benefits with concerns over accuracy, bias, and the human touch in patient care.
Advertisement
Advertisement
One of the fastest-evolving topics in today’s world is artificial intelligence (AI) and its practical application in fields such as medicine.
Related to this article
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.
Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.
Tulisokibart met its HiSCR50 primary endpoint at 16 weeks in the phase 2b MK-7240-012 trial assessing moderate to severe hidradenitis suppurativa.
Zasocitinib achieved PASI 100 in 36.5% of patients vs 13.9% with deucravacitinib at week 16 in the phase 3 LATITUDE Atlas psoriasis trial.
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
Advertisement
Advertisement